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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide. 
NAFLD is an umbrella term for a range of liver conditions affecting people who drink little 
to no alcohol Different methods are employed in the diagnosis of NAFLD. Certain drugs, 
genetics, lifestyle factors have been implicated in the development of NAFLD. NAFLD 
symptoms are asymptomatic but indicated when there is unexplained persistent eleva-
tion of liver enzyme levels. Nutrition and lifestyle modifications are widely prescribed as 
helpful in the prevention and treatment of Non-Alcoholic Fatty Liver disease (NAFLD). 
Dietary and lifestyle modifications are apparent measures considering the disease asso-
ciation with obesity, diabetes, and cardiovascular disease which many reviews have 
linked to the condition. Reduction in body weight, involvement in both aerobic and 
anaerobic exercises, conscious intake in the types of fat and carbohydrates are helpful 
in the management of NAFLD. This chapter highlights the various theories and prin-
ciples underlying nutrition and lifestyle modifications in the prevention and treatment 
of NAFLDs.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and is 
a risk factor for both hepatic and cardiometabolic mortality [1, 2]. A meta-analysis of preva-
lence, incidence and outcome of NAFLD following publications on pubmed from 1989 to 
2015 estimated global prevalence at 25.24% (95% CI: 22.10–28.65) with highest prevalence in 
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the Middle East 31.79% (13.48–58.23) and South America 30.45% (22.74–39.44) and lowest in 
Africa 13.48% (5.69–28.69) [2]. NAFLD describes a range of conditions caused by a build-up 
of fat within liver cells and can be divided into four stages namely:
1. Simple fatty liver (hepatic steatosis). Under normal conditions, very little fat is stored in 
liver cells of humans. Hepatic steatosis therefore refers to a situation where excess fat ac-
cumulates in the hepatic cells. Sometimes simple fatty liver does not cause any harm to the 
liver or pose health risks. However, in some instances it leads to NAFLD and its severe 
forms and that is where the problem arises.
2. Non-alcoholic steatohepatitis (NASH). This expression is much less common than 
NAFLD. Here, the excess fat stored in the liver cells is associated with inflammation of 
the liver.
3. Fibrosis: This is associated with persistent hepatitis, including steatohepatitis and may 
lead to scarring of the liver tissue (fibrosis). This is not life threatening since when fibrosis 
some of the liver cells that continue to perform its functions.
4. Cirrhosis: This stage of a liver disease can be life threatening because normal liver tissues 
are replaced by a lot of fibrosis. The structure and function of the liver are therefore modi-
fied. There are different scientific means of detecting liver diseases.
2. Diagnosis
There are different methods of diagnosing NAFLD. The test ranges from metabolic syndrome 
assessment, detecting metabolites in the blood as well as enzymes such as Alanine trans-
aminase (ALT) and Aspartate Aminotransferase (AST) [3]. Medical imaging and sonographic 
techniques are also performed to create an image of the liver. Further tests such as fibroscan 
and biopsy may be conducted apart from those listed earlier to determine the stage of the 
liver disease [4].
3. Risk factors
A wide range of diseases and conditions can predispose one to non-alcoholic fatty liver dis-
ease (NAFLD). Non-alcoholic steatohepatitis expresses itself among some sub-populations 
such as older people, diabetics and the obese. Certain drugs and hepatitis have been impli-
cated in the development of NAFLD as well. Some risks are usually from lifestyle origin. 
These include:
• High cholesterol and triglycerides levels,
• Metabolic syndrome,
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• Central adiposity,
• Polycystic ovary syndrome,
• Sleep apnea,
• Genetics,
• Hypothyroidism,
• Hypopituitarism [5].
Nutritional factors have also been cited as risks in the development of the disease. These 
include rapid weight loss, total parenteral nutrition, starvation and protein-calorie malnutri-
tion [6]. The most common risk factor associated with NAFLD is the presence of the metabolic 
syndrome. The metabolic syndrome is defined by the presence of 3 or more of the following 
criteria (Table 1): (1) increased waist circumference, (2) hypertriglyceridemia, (3) hyperten-
sion, (4) high fasting glucose, and (5) a low high-density lipoprotein (HDL) level.
4. Signs and symptoms and management
Nonalcoholic fatty liver disease occurs in every age group but especially in people in their 
40s and 50s. The condition is also closely linked to metabolic syndrome, which is a cluster 
of abnormalities including increased abdominal fat, poor ability to use the hormone insulin, 
high blood pressure and high blood levels of triglycerides. NAFLD symptoms are asymptom-
atic but indicated when there is unexplained persistent elevation of liver enzyme levels after 
hepatitis and other chronic liver diseases have been excluded. However, at certain stages of 
the disease, patients are malaise, fatigue, and right upper quadrant or diffuse abdominal dis-
comfort. Hepatomegaly is found on clinical examination. When there is cirrhosis there may 
be; spider angiomata, ascites, splenomegaly, hard liver border, ascites, portal hypertension 
and jaundice or pruritus [7].
Parameter* Value
Impaired glucose tolerance Fasting blood glucose level ≥ 110 mg/dL
High blood pressure ≥130/85 mm Hg
Elevated triglyceride levels >250 mg/dL
Low high-density lipoprotein level <40 mg/dL for men;
<50 mg/dL for women
Abdominal obesity Waist: >102 cm (40 inches) for men;
>88 cm (35 inches) for women
*Metabolic syndrome is diagnosed by the presence of 2 or more of these parameters.
Source: [2].
Table 1. Diagnostic criteria for metabolic syndrome.
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Clinical evaluation includes a careful history and physical examination. It is relevant to inquire 
about excess alcohol consumption which is defined as intakes greater than 30 g/day for men 
and greater than 20 g/day for women within the past 5 years. A drink is 350 mL (12 oz) of beer, 
120 mL (4 oz) of wine, and 45 mL (1.5 oz) of hard liquor each contain 10 g of alcohol.
There are several approaches to managing NAFLD. Hepatoprotective therapy, antioxidants 
insulin-sensitizing agents and treatment of obesity are part of these. However, this text limits 
itself to the nutritional management of the NAFLD. Key to nutritional therapeutic proce-
dures are lifestyle changes in diet and improving exercise habits in addition to the control of 
comorbidities which are secondary to the development of NAFLD [8]. For instance, bile acid 
derivatives and associated compounds that influence bile acid related are becoming promi-
nent therapeutic agents for NAFLD [9, 10, 11]. The immediate associated lifestyle causes of 
NAFLD are targeted in the management of the disease condition.
5. Obesity and genetics
Obesity when combined with physical inactivity and genetic predisposition, has been 
directly associated with metabolic syndrome and NAFLD among some adult populations 
[12, 2]. Obesity itself is the failure of normal homeostatic regulation of energy utilization 
[9]. NAFLD can be a precursor to developing metabolic syndrome or insulin resistance [10]. 
Data suggest that about 80% of adults who are class 1 and/or 2 obese and 90% morbid obese 
according to the World Health Organization classification are at risk of having NAFLD 
[13]. Body weight loss can alter the cellular activity of adipose tissue and reverse many 
of the negative consequences of NAFLD. The excess fat and energy content of a meal has 
been associated with NAFLD development in healthy populations [14, 15]. Insulin resis-
tance, oxidative stress, and cytokine toxicity results due to obesity and these factors have 
been implicated in the pathogenesis of NAFLD [16]. Among these factors, central adiposity 
and insulin resistance have direct association with hepatic fat content and visceral adipos-
ity [17–19]. Polymorphisms (genetic variations) in the single-nucleotide polymorphisms 
(SNPs) T455C and C482T in APOC3 are associated with fatty liver disease. The carriers of 
T-455C, C-482 T, or both (not additive) had a 30% increase in fasting plasma apolipoprotein 
C3, 60% increase in fasting plasma triglyceride and 46% reduction in plasma triglyceride 
clearance. Oxidative stress, hormonal imbalances, and mitochondrial abnormalities can be 
potential causes.
6. Total fat
Dietary composition of a meal in terms of the macro-molecule distribution has a positive rela-
tion with the development of NAFLD. The amount and type of dietary fat may directly affect 
liver fat content, with high-fat diets being potentially harmful [20]. It has also been shown 
that a high ratio of omega-6 to omega-3 polyunsaturated fatty acids (PUFAs) and an increased 
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intake of saturated and trans fatty acids are associated with NAFLD [21–23]. It was noted that 
when severely obese patients were fed diets containing higher percentage of total fat beyond 
recommended ranges, the risk of developing NALFD increased [24]. The deduction therefore 
was that the type of fat ingested rather than the amount is associated with NAFLD in obese 
individuals.
7. Saturated fatty acids
Saturated fatty acid component in meals has been shown to induce insulin resistance espe-
cially among the obese [25–27]. In epidemiologic studies, both total fat and saturated fat in 
the diet had significant correlation with triglyceride content in hepatic cells [28, 29]. In a dou-
ble-blind randomized controlled trial of two reduced-fat diets, compared with a control diet 
both reduced-fat diets decreased amount of low density lipoprotein cholesterol (LDLc) in 
healthy males [30]. There was a decrease in high density lipoprotein cholesterol (HDLc) and 
increase in triglyceride levels increased with the reduced-fat diets. The authors concluded 
that reduced saturated fat intake (below 10%) may benefit patients with NAFLD. It was also 
observed that, low total fat and low saturated fat diet (23% fat and 7% saturated fat) predicted 
changes in HDLc and LDLc but not the amount of fat in the hepatocytes [31].
8. Trans fatty acids
Trans fatty acids are positively associated with an increase in inflammatory processes, plasma 
triglycerides, and cholesterol as well as a reduction in HDLc level [32, 33]. Animal studies 
have shown positive relationships between the increased consumption of trans fatty acids 
from oxidized oils and liver inflammation [34, 35].
9. Polyunsaturated fatty acids (PUFAs)
Essential fatty acid, Omega-3 (which is a type of polyunsaturated fatty acids) PUFA levels are 
decreased in the hepatic tissue of people with NAFLD [22, 36] A higher omega-6 to omega-3 
PUFA ratio may contribute to the development of a fatty liver within the hepatocytes of peo-
ple NAFLD [36].
10. High carbohydrate intake
High carbohydrate intake especially the amount and type of carbohydrate consumed have 
an important impact on the development of NAFLD [37]. Simple carbohydrates intakes 
can lead to the development of NAFLD [38]. Meals high in carbohydrates lead to increased 
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amounts of circulating insulin, which contribute to elevated triglyceride concentrations 
even under isocaloric conditions [39, 40]. A higher carbohydrate intake more than the 
recommended daily values has been positively associated with liver inflammation and 
NAFLD [24].
Coupled with a low-fat meal, high-carbohydrate meal promotes the development of a NAFLD 
through increased de novo fatty acid and triglyceride synthesis [41].
11. High-fructose corn syrup intake
Epidemiological data suggest that dietary pattern and an increased intake of simple sugars, 
especially fructose is associated with the development of NAFLD [42, 43]. The link is not 
too clear although it is assumed that the carbohydrates components increased risk of fatty 
infiltration of the liver or muscle. Therefore it was hypothesized that the link is through 
both indirect and direct mechanisms [44, 45]. Indirect association manifest itself through 
the adverse metabolic effects that can increase the risk of developing NAFLD. Fructose may 
cause hepatotoxic damage as a form of direct route link with NAFLD. Studies [46–49] have 
suggested that increased fructose consumption augments fat mass, de novo lipogenesis, 
and inflammation. There is also induction of insulin resistance and fasting and postpran-
dial triglycerides, which in turn, can result in liver steatosis. In other studies [50, 51], sugar-
sweetened beverage consumption was found to be associated with fatty liver independent 
of body mass index of the individuals. Direct positive association was found between the 
amount of fructose consumed and the development of NAFLD [52, 53]. Age and frequency 
of consuming fructose-based food was also found to be related to liver inflammation and 
NAFLD [54].
12. Physical inactivity
Physical activity has been documented to improve health and hence the World Health 
Organization recommendations for aerobic an anaerobic exercises across the life span. 
Physical inactivity however, has been associated with NAFLD. Using matched controls for 
age and gender, only about one-fifth of individuals with NAFLD met recommendations for 
physical activity [55, 56]. Among 349 individuals studied, the NAFLD group engaged in less 
physical activity, including total, aerobic, and resistance [55].
It has been noted that decreased physical activity correlates with intra-hepatic fat, decreased 
cellular insulin sensitivity, and increased central adiposity [57, 58]. Sedentary time alone is 
associated with metabolic status. Sedentary times predicted higher levels of fasting insulin, 
independent of the amount of time spent engaging in moderate- or vigorous-intensity activ-
ity [59]. Therefore to improve metabolic health it is generally important to reduce sedentary 
lifestyle even when one meets the requirements for physical activity.
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13. Treatments
Aggressive pursuit of modified lifestyle modifications coupled with dietary changes are criti-
cal in treating NAFLD when body weight is the underlying cause. That is because dietary 
macronutrient composition, physical activity, and all play critical roles in successful weight 
reduction. Weight loss is effective for improving NAFLD as it positively influences insulin 
sensitivity and dyslipidemia.
14. Body weight loss
It was found that about 9% body weight loss significantly improves NAFLD [60]. The result 
was thought to be due to improvements in inflammation and steatosis. Reduction in body 
weight through lowering of daily caloric intake of about 200 kcal/day improved liver cellular 
structure histology and enzymes function. A 10% body weight reduction resulted in a 45% 
reduction in liver fat content [61]. Lifestyle modification through dietary intake, exercise, and 
behavior modification with the guidelines from health experts has been show to lead to reso-
lution in NALFD [62]. A weight reduction of about 7% was therefore recommended [63]. A 
combination of diet and exercise reduces fibrosis and amount of liver fat by an average of 40% 
[64–66]. The degree of hepatic fat reduction is related to the intensity of the lifestyle mediation 
and normally required a weight loss range of 5–10% is suggested.
15. Bariatric surgery
Among persons with higher grades of obesity, physical remedy such as reduction in dietary 
intake and physical activities does not result in resolution of NAFLD. Other means such as bar-
iatric surgery is the most effective strategy to achieve and maintain weight loss [67]. Results from 
several uncontrolled studies [68–70] and controlled studies [71, 72] indicated that body weight 
loss achieved through bariatric surgery reduces amount of liver enzymes and improves NAFLD.
A study found an association between bariatric surgery and lower serum alanine transfer-
ase and aspartate aminotransferase levels at two and 10 years follow-up [73] and histologi-
cal improvements [74]. Steatosis, steatohepatitis, and fibrosis improved among majority of 
patients that have undergone surgery [75]. It is worth noting that hepatic decompensation 
can occur after gastric bypass so decision to opt for this should be taken with great care [3].
16. Nutrient content and healthful fats
Dietary composition can directly manipulate NAFLD progress. Changing either the composi-
tion of the macronutrient or micronutrient content can directly affect the level of inflammation, 
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amount of serum lipids and insulin resistance [49]. Inverse association was found between 
Mediterranean diet consumption and cardiovascular disease risk [76]. Among obese women 
and overweight men, a low-fat diet decreased hepatic fat compared with a high-fat diet [64, 77]. 
The dietary recommendation is that the diet contain less than 7% saturated fats, less than 1% of 
trans fats and 25–35% of the calorific intake should be total fat among which is polyunsaturated 
fatty acid.
17. Monounsaturated fats
It was found that replacing carbohydrate intake with monounsaturated fatty acids (MUFAs) 
to about 32 g/day increases triglyceride-rich lipoprotein catabolism [30]. This can lead to reso-
lution of NAFLD. This finding is supported by epidemiological studies [31, 78]. Olive oil 
which contains about 73% MUFAs appears to provide a direct benefit in improving plasma 
lipids and possible NAFLD [79]. In randomized trials, [80, 81] isocaloric low-fat/high-carbo-
hydrate diet improved hepatic fat and improved insulin sensitivity. The diet was composed 
of 50% MUFAs and 18% omega-3 PUFAs, 40% from carbohydrate, and 20% protein. These 
findings were independent of body weight loss of patients.
18. Omega-3 Omega-6 PUFAs
Evidence from epidemiologic and randomized controlled trials indicate that supplemen-
tation with omega-3 PUFAs lowers triglyceride levels and reduces the risk of coronary 
heart disease and mortality.94,95 High consumption of omega-3 PUFAs derived from fish 
diminishes hepatic triglyceride lipoprotein secretion and inhibits de novo lipogenesis. 
[82]. Using the Therapeutic Lifestyle Change diet criteria with a diet high in fish-derived 
omega-3 fatty acid (1.23 g/day EPA + DHA) vs. a low fish diet (0.27 g/day EPA + DHA) 
for 24 weeks, the higher fish diet decreased plasma triglycerides by 24%. Three human 
clinical trials support these findings by showing that giving patients with NAFLD 
omega-3 PUFAs (1 to 2.7 g/day for six to 12 months) improved hepatic steatosis, inflam-
mation, and fibrosis [82, 83]. Capanni and Spadaro both demonstrated that triglyceride 
levels decreased 25 to 37 mg/dL when patients’ diets were supplemented with 1 to 2 g 
of omega-3 PUFAs per day for six and 12 months, respectively. This was thought to be 
through diminishes hepatic triglyceride lipoprotein secretion and inhibition de novo lipo-
genesis [82–84]. Diets based on therapeutic lifestyle change criteria supports improve-
ments in NAFLD as the diet improves liver steatosis, inflammation, and fibrosis [85]. In 
a non-controlled trial, omega-6 PUFAs (15% of energy as linoleic acid) reduced liver fat 
compared with a diet high in saturated fatty acids in abdominally obese patients [86]. A 
diet consisting of mainly reduced simple carbohydrate may confer similar benefits among 
NALFD patients [87, 88].
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19. Low sugar intake
Diet designed to produce a caloric deficit of 500 to1000 kcal/day is advised. Reduction of dietary 
carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve 
the lipid profile in overweight patients. Diets with less carbohydrate and more fat have relatively 
greater benefits in NAFLD management [89, 90]. Hypocaloric diet made up from 40% carbo-
hydrate and 45% fat decreased serum alanine transaminase concentration than did a higher-
carbohydrate (60%), low-fat diet (25% fat) [91]. Low-carbohydrate caloric restriction significantly 
improved hepatic insulin sensitivity. Diets with less carbohydrate and more fat have relatively 
greater benefits for insulin levels, triglycerides, and HDL cholesterol concentrations than do 
hypocaloric, low-fat diets. A hypocaloric diet moderately lower in carbohydrate (40% carbo-
hydrate and 45% fat) decreased serum alanine transaminase concentrations to a greater degree 
than did a higher-carbohydrate, low-fat diet (60% carbohydrate and 25% fat).106 For individuals 
with NAFLD who were glucose intolerant, the low-carbohydrate caloric restriction significantly 
improved hepatic insulin sensitivity compared with the low-fat diet. In contrast, changes in vis-
ceral fat mass and insulin sensitivity were similar between a low-calorie, reduced-carbohydrate 
diet (fewer than 90 g of carbohydrate) and a reduced-fat diet (less than 20% fat). The World 
Health Organization recommends that the daily intake of added sugars makes up no more than 
10% of total energy. The American Heart Association recommends limiting the amount of added 
sugars to no more than one-half of daily discretionary calories, which for women is approxi-
mately 100 kcal/day (6 tsp. of sugar) and for men is 150 kcal/day (9 tsp. of sugar).
20. Physical activity therapy
Physical activity enhances insulin sensitivity and favorably modifies lipids independent of 
weight loss [92, 93] Data suggest that there is improvement in cellular liver characteristics 
when NALFD individuals become active [94]. Exercise can lead to improvement in insulin 
sensitivity which intends contributes to the fatty acid delivery to the liver [95]. Improvement 
in insulin resistance and may decrease hepatic steatosis, inflammation, and disease progres-
sion in NAFLD [96, 97]. Four studies have investigated the effects of exercise without dietary 
modification on hepatic steatosis. Exercise can independently results in reduction in the fat in 
the hepatocytes without a significant weight change [98–101].
21. Exercise intensity and duration
Both intermittent and daily exercise helps achieve weight loss and improve insulin sensitivity 
[102]. Intensity and duration contribute to energy expenditure and therefore can lead to insu-
lin sensitivity, triglycerides, and serum glucose amount [103]. Vigorous exercise and doubling 
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the duration of vigorous exercise was associated with decreased odds of developing fat in the 
liver [104]. Increased exercise by 60 minutes or more per week significantly reduced body 
weight and all liver enzymes [105]. Regular aerobic exercise for half an hour at least per day 
at 60–70% max heart rate for least 5 days per week reduces liver alanine transaminase levels 
[106].
22. Aerobic and resistance exercises
Increased aerobic exercise has been associated with improvement in the metabolic parameters 
associated with NAFLD [61, 94, 106]. Combined aerobic and resistance exercises have been 
shown to be more effective than aerobic exercise alone for resolving inflammation and cardio-
vascular risk factors [107]. An intervention of 30 minutes of aerobic exercise and 20 minutes 
of resistance exercise three times per week was found to be associated with improvements in 
hepatic fat among NAFLD patients [108]. This combination activity improves hepatic insulin 
sensitivity [100] reduction in liver fat [109]. Both findings were independent of body weight 
reduction. Antioxidant treatments such as vitamins and minerals supplementation have been 
mentioned to decrease oxidative stress and improve oxidative injury among NAFLD patients.
23. Vitamin E
In theory, vitamin E and other vitamins called antioxidants could help protect the liver by 
reducing or neutralizing the damage caused by inflammation. But more research is needed. 
Some evidence suggests vitamin E supplements may be helpful for people with liver damage 
caused by nonalcoholic fatty liver disease [110]. But vitamin E has been linked with increased 
risk of death and, in men, an increased risk of prostate cancer. Several small trials in humans 
with NAFLD have supported an effect of tocopherol (vitamin E) on the improvement of trans-
aminase levels but there have been discordant results in histologic improvement [111]. There 
was a significant improvement in hepatic steatosis with vitamin E intakes at levels of 800 to 
1000 IU/day [112, 113] Higher intakes of the vitamin can be fatal in most cases [114, 115].
24. Vitamin D
Vitamin D may play an important role in modifying the risk of cardio metabolic outcomes 
[116, 117]. Serum 25-hydroxy vitamin D concentrations were correlated with NAFLD in terms 
of liver steatosis, inflammation and fibrosis [118].
25. EPA + DHA
The evidence supporting the use of omega-3 PUFAs for treating NAFLD have consisted of 
small sample sizes and laden with errors [118, 119].
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26. Probiotics
Gut microbiota has been associated with the development of obesity-related NAFLD 
[120]. Probiotics may improve liver enzymes and decrease markers of lipid peroxidation 
[121, 122]. The use of prebiotics and probiotics is to modify the microbiota as preven-
tive or therapeutic strategies [123]. Their beneficial effects on NAFLD have been limited 
human studies [124]. Consuming a tablet containing 500 million Lactobacillus bulgaricus 
and Streptococcus thermophilus for 3 months improved levels of liver enzyme in patients 
with NAFLD [124].
27. Other nutrients
Ginger (Zingiber officinale) can improve insulin sensitivity and reduce hepatic fat content [125]. 
In studies of people with non-alcoholic fatty liver disease, those who reported drinking coffee 
had less liver damage than those who drank little or no coffee. It’s not clear how coffee may 
influence liver damage or how much coffee you’d need to drink in order to benefit. Table 2 
summarizes the nutritional guidelines in the management and treatment of NAFLD.
Weight loss 10% of initial body weight over 6 months
Maintenance of weight loss
Bariatric surgery when individuals qualify
Calorie intake 1200 to 1500 daily
*Energy deficit of 500 kcal/day based on Mifflin-St Jeor formula
Total fat ≤ 35% of total calories
Monounsaturated fatty acids 15–25% of total calories
Polyunsaturated fatty acids 5–10% of total calories
Omega-3 fatty acids
Saturated fatty acids 7–10% of total calories
Carbohydrate 50% of total calories
> 50% carbohydrate sources from whole grains
Avoid high-fructose corn syrup
Added sugars <10% of total calories
Protein 15% of total calories
Lean and vegetable protein
Antioxidants None
Physical activity ≥ 150 minutes/week at moderate intensity or ≥75 minutes/week at vigorous 
intensity
Cardiovascular exercise five times weekly
Resistance training two or more times weekly
Decrease time spent sedentary
Source: [65, 81, 83].
Table 2. Guidelines in the management and treatment of NAFLD.
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